Pieris Pharmaceuticals Appoints Immuno-Oncology Expert, Holbrook Kohrt, M.D., Ph.D., to Spearhead Immuno-Oncology Efforts and Initiates Research Collaboration With Leading Cancer Research Center
Marketwired - Thu May 14, 7:30AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its patented and proprietary Anticalin® biotherapeutic technologies, announced today that it has engaged Dr. Holbrook Kohrt, M.D., Ph.D. as Senior Advisor Translational Medicine Immuno-oncology.
Pieris Pharmaceuticals Reports First Quarter 2015 Financial Results
Marketwired - Wed May 13, 4:30PM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, reported today financial results for the first quarter ended March 31, 2015 and provided an update on the Company's recent developments.
Pieris Pharmaceuticals Appoints Former Celgene and Sanofi Executive, Jean-Pierre Bizzari, M.D., to Its Board of Directors
Marketwired - Tue May 12, 9:54AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its patented and proprietary Anticalin® biotherapeutic technologies, announced today that Jean-Pierre Bizzari, M.D., has joined the Company's Board bringing the total number of directors to six.
CELGZ: 2.60 (-0.10)
Pieris Pharmaceuticals to Present at the 2015 UBS Global Healthcare Conference on May 19th, 2015
Marketwired - Thu May 07, 8:53AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its patented and proprietary Anticalin® biotherapeutic technologies, announced today that its President and CEO, Stephen Yoder, will present at the 2015 UBS Global Healthcare Conference. The conference is being held on May 18-20, 2015 at The Sheraton New York Times Square Hotel.
Pieris Pharmaceuticals to Host First Quarter 2015 Investor Call on May 14th
Marketwired - Tue May 05, 7:31AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that it will conduct a conference call on Thursday, May 14 at 10:00 AM (EDT) to discuss first quarter 2015 business and financial results.
Pieris' Anticalin Platform Could Revolutionize Drug Development
Jason Napodano, CFA - at Seeking Alpha - Fri Apr 10, 3:28PM CDT
Pieris Pharmaceuticals and The University of Melbourne Receive Research Grant to Advance Immunological Diseases Program
Marketwired - Mon Mar 30, 5:31AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS) and The University of Melbourne today announced the receipt by the University of a research grant to further develop Pieris' novel protein Anticalin®-brand therapeutic, PRS-060, in immunological diseases. The grant -- which will support Pieris' Australian subsidiary, Pieris Australia, and is disbursed by Australia's peak medical research funding body, the National Health and Medical Research Council (NHMRC) -- totals more than $AUS 500,000 and covers activities to advance PRS-060 for inhaled delivery to treat asthmatics.
Pieris Pharmaceuticals Reports Full-Year 2014 Financial Results and Provides Corporate Update
Marketwired - Wed Mar 25, 4:05PM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS) (the "Company" or "Pieris"
Pieris to Present at the 17th Annual BIO CEO & Investor Conference
Marketwire Canada - Tue Feb 03, 8:11AM CST
Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS), a biotechnology company advancing its proprietary AnticalinA® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will be presenting at The 17th Annual BIO CEO & Investor Conference to be held at the Waldorf Astoria in New York City on Monday, February 9 at 5:00 PM (ET).
Pieris Pharmaceuticals, Inc. Completes Private Placement, Raises $13.6M
Marketwired - Tue Dec 23, 3:56PM CST
Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS) (formerly Marika, Inc.), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today the successful completion of its private placement offering as part of its alternative public offering announced on December 18, 2014. Shares of the Company's common stock are quoted on the OTC Market under the symbol "PIRS."
Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million
Marketwired - Thu Dec 18, 10:18AM CST
Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS) (formerly Marika, Inc.), a Nevada corporation, announced today its successful completion of a share exchange transaction with Pieris AG, a German stock corporation pursuant to which Pieris AG became a wholly-owned subsidiary of the Company. The combined entity is named Pieris Pharmaceuticals, Inc. and will focus solely on the business of Pieris AG, a clinical-stage biopharmaceutical company dedicated to the discovery and development of its proprietary Anticalin® class of biotherapeutics. The share exchange transaction was effected on December 17, 2014, and beginning on December 18, 2014, Pieris will trade under the symbol "PIRS" on the OTC Markets.